Undervalued PharmaCyte Biotech Moves Closer to Phase 2b Clinical Trial Launch Featuring Breakthrough Technology

Oct 08, 2015, 09:15 ET from Goldman Small Cap Research

BALTIMORE, Maryland, October 8, 2015 /PRNewswire/ --

Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has published a new sponsored research report on PharmaCyte Biotech, Inc. (OTCQB - PMCB), a publicly traded, clinical stage biotechnology company focused on developing and preparing treatments for cancer and diabetes. To view the sponsored research report, along with disclosures and disclaimers, or to download it and previous articles in their entirety, please visit http://www.GoldmanResearch.com.  

In the report, analyst Rob Goldman discusses the remaining steps requiring completion prior to launching PharmaCyte Biotech's proposed Phase 2b pancreatic cancer clinical trial, the low valuation afforded the Company relative to its peer group, and the potential impact of its breakthrough technology on current methods used to treat cancer and diabetes.

According to Goldman, "PMCB could soon announce it has been awarded Orphan Drug Status in Europe for its pancreatic cancer treatment, which follows a similar designation in the U.S. This award would be the first of several catalyst-driving milestones over the next few quarters. In our view, PMCB is in the middle/late innings of its preparation to initiate a highly anticipated multi-site Phase 2b clinical trial in 1Q16, which should serve as "the" event for the Company. Moreover, the overlooked PMCB stock trades at a significant discount to our Pancreatic Cancer Peer Group. Development progress culminating in the commencement of the Phase 2b should sharply impact this news-driven stock, thus narrowing the peer group discount."

Goldman also commented on the Company's diabetes treatment development. "Early 2015 studies suggest that PharmaCyte Biotech's Cell-in-a-Box® platform could be considered the Holy Grail of treatment for diabetes. This platform, when used along with Melligen cells, could become a treatment that has clear advantages over current insulin injection and pump therapies for Type 1 diabetes. Therefore, the PMCB Cell-in-a-Box® -based treatment system approach could potentially replace these therapies.  That is why directly or indirectly affecting millions, progress on this front should eventually be far more lucrative than even its anti-cancer efforts."  

"The bottom line with PMCB is that the very nature of the Cell-in-a-Box®-based disease treatments and their therapeutic indications is usually unheard of for a Company of this size and these therapies may ultimately be used to treat multiple forms of cancer and diabetes which represent the biggest treatment markets.  Therefore, we may be witnessing the dawn of new therapies for these diseases," commented Goldman.

About Goldman Small Cap Research: Founded in 2009 by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces sponsored and non-sponsored small cap and microcap stock research reports, articles, daily stock market blogs, and popular investment newsletters. Goldman Small Cap Research is not in any way affiliated with Goldman Sachs & Co.

This press release contains excerpts of our most recently published sponsored research report on PharmaCyte Biotech, Inc.  The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research relied solely upon information derived from PharmaCyte Biotech Inc. ("the Company") authorized press releases or legal disclosures made in its filings with the U.S. Securities and Exchange Commission http://www.sec.gov.

Separate from the factual content of our articles about the Company, we may from time to time include our own opinions about the Company, its business, markets and opportunities. Any opinions we may offer about the Company are solely our own, and are made in reliance upon our rights under the First Amendment to the U.S. Constitution, and are provided solely for the general opinionated discussion of our readers. Our opinions should not be considered to be complete, precise, accurate, or current investment advice. Statements herein may contain forward-looking statements and are subject to significant risks and uncertainties affecting results.

A Goldman Small Cap Research report, update, newsletter, or article is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed is to be used for informational purposes only.  Please read all associated full disclosures, disclaimers, and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit http://www.goldmanresearch.com. In 2015, Goldman Small Cap Research has been compensated by a third party in the amount of $18,000 for investment research services that includes the publication of research reports, updates, and a series of articles.

About PharmaCyte Biotech.: PharmaCyte Biotech Inc. (OTCQB - PMCB) is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box®. This unique and patented technology will be used as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer, and diabetes are being built. More information on PMCB can be found at http://www.PharmaCyteBiotech.com.

Goldman Small Cap Research
Rob Goldman, Analyst

SOURCE Goldman Small Cap Research